tbuckley/cabot-search huggingface dataset:
Abstract 3121: c-Jun as a target in pancreatic cancer.
Authors: Anjali V. Sheahan, Levon M. Khachigian
Journal: Cancer Research (2013)

Abstract Prognosis for pancreatic cancer is especially poor, with a 5% survival rate. Current FDA-approved therapeutics gemcitabine and erlotinib extend patient survival by a mere two months. As the disease is asymptomatic, patients are generally diagnosed at later stages of the disease. Consequentially, only 15-20% of patients present with resectable tumors. Further, aggressive metastasis often occurs after surgical intervention, resulting in the death of 75% of patients within five years. These statistics indicate an unmet need for more effective therapeutic strategies to combat pancreatic cancer. c-Jun is a component of the AP-1 early response transcription factor. It is expressed in 87% of primary pancreatic cancer lesions and in several pancreatic cancer cell lines. c-Jun overexpression has been linked to metastasis in numerous cancer models and previous work in our laboratory has demonstrated the efficacy of a DNAzyme against c-Jun for the suppression of tumor growth and angiogenesis in in vivo models of basal and squamous cell carcinoma. We sought to explore the role of c-Jun in pancreatic cancer and the therapeutic potential of gene silencing of endogenous c-Jun. We confirmed serum-inducible c-Jun expression at the mRNA level using qRT-PCR in two in vitro models of pancreatic adenocarcinoma, PANC-1 and MIA PaCa-2. This is consistent with Western blot data, which confirm expression of both c-Jun as well as its phosphorylated form (p-c-Jun) at the protein level. Optimal uptake of a FITC-labeled siRNA into these cell lines was achieved using DOTAP/DOPE transfection reagent. We subsequently demonstrated that the effective blockade of c-Jun and p-c-Jun could be achieved with siRNA targeting human endogenous c-Jun. At the functional level, while blockade of c-Jun had no apparent effect on cell proliferation, PANC-1 and MIA PaCa-2 cell migration and invasion were markedly reduced. This was demonstrated using transwell assays. Interestingly, this effect was enhanced in cells that were also treated with gemcitabine. Further, we showed that MMP-1 expression was inhibited in MIA PaCa-2 cells treated with siRNA targeting c-Jun. We have also identified Cystatin F, MDM2, MET, MMP-13 and NF2 as potential downstream targets of c-Jun using a human tumor metastasis PCR array. This in vitro data confirms the expression and activation of c-Jun in pancreatic cancer cells, and demonstrate a functional role for c-Jun in pancreatic cancer cell migration and invasion, which underpin metastasis. We are in the process of validating these results in vivo employing shRNA to generate a stable knockdown of c-Jun in pancreatic cancer cells (MIA PaCa-2). Citation Format: Anjali V. Sheahan, Levon M. Khachigian. c-Jun as a target in pancreatic cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3121. doi:10.1158/1538-7445.AM2013-3121
Expert Board Gives Advice to NCI on Breast Cancer Screening Guidelines
Authors: N. Volkers
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Expert Board Gives Advice to NCI on Breast Cancer Screening Guidelines Get access Nancy Volkers Nancy Volkers Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 22, 17 November 1993, Page 1795, https://doi.org/10.1093/jnci/85.22.1795 Published: 17 November 1993
COLEDOCOLITIASIS DE DIFICIL O PELIGROSA EXTRACCIÓN: RESULTADOS DE 7 AÑOS DE EXPERIENCIA UTILIZANDO BALON DE GRAN DIAMETRO
Authors: J Espinel, E Pinedo, B Alvarez, L Vaquero, AB Dominguez
Journal: Endoscopy (2012)

Introducción: La dilatación de la papila con balón de gran diámetro es una técnica eficaz en la extracción de colédocolitiasis. Objetivo: Valorar la eficacia y seguridad de la dilatación hidrostática con balones de gran diámetro en el tratamiento de la colédocolitiasis, en pacientes con factores que dificultan o hacen peligrosa la extracción, por las características de los cálculos o de la anatomía peripapilar. Material y método: Estudio prospectivo que incluye 243 pacientes (145 mujeres/98 hombres) a los que se realizó dilatación hidrostática de la papila con balones de gran diámetro entre junio de 2005 y junio de 2012 por presentar cálculos de gran tamaño, múltiples, colédoco distal afilado, papila peri/intradiverticular, esfinterotomía previa o Billroth-II. Se emplearon dilatadores CRE de diámetros entre 12 y 20mm. Resultados: Se consiguió la extracción de los cálculos en 238/243 pacientes (97,9%) [234 pacientes (96,2%) en 1 sesión; 4 pacientes (1,6%) en 2 sesiones]. Se precisó litotricia en 15 pacientes (6,1%). La mayor parte de las exploraciones (86,8%) no requirieron tiempos prolongados para la extracción. Hubo 9 complicaciones leves (3,7%). Se detectó hiperamilasemia en el 11,1% de los pacientes. Conclusiones: La dilatación hidrostática de la papila con balones de gran diámetro es una técnica sencilla, eficaz y segura en la extracción de cálculos difíciles de la vía biliar, sin incrementar el tiempo de la exploración, ni las complicaciones, reduciendo la necesidad de litotricia. Después de 7 años de experiencia, se mantienen estas conclusiones que creemos aplicables ante las indicaciones expuestas.
SEX-SPECIFIC MORTALITY RISK BY QRS MORPHOLOGY AND DURATION IN PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY: RESULTS FROM THE NCDR®
Authors: Robbert Zusterzeel, Jeptha Curtis, Daniel Canos, William E. Sanders, Kimberly A. Selzman, Ileana Pina, Erica Spatz, Haikun Bao, Angelo Ponirakis, Paul Varosy, Frederick Masoudi, David Strauss
Journal: Journal of the American College of Cardiology (2014)
Reply to Hu
Authors: T. Baron
Journal: Endoscopy (2011)

I appreciate the comments raised by Dr Hu regarding the method I described for transferring a nasobiliary tube from the mouth to the nose, and especially the concerns raised about nasal trauma and endoscope damage. Our patient was actually edentulous, though a bite block was in place nonetheless. The self-limited nasal bleeding our patient experienced may also have been due to the prior unsuccessful attempt at passage of the transfer tube. Using the technique I described the assistant at the head of the bed needs to ensure that the bite block is not expelled if moderate sedation or monitored anesthesia care is administered.
Case 22-1992
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, N.G. Guerina, J. Sullinger
Journal: New England Journal of Medicine (1992)

Presentation of CaseA 6 1/2-year-old girl was admitted to the hospital because of status epilepticus.The patient was the only child of a mother 30 years old at delivery and a father 35 years old. The child was delivered by cesarean section, reportedly because she was 31 days overdue. Her early growth and development were normal, and her immunizations were up to date. She was well until three weeks before entry, when a sore throat and headache developed, with a temperature of 37.2°C. Twenty-four hours later an erythematous rash with a texture of "fine sandpaper" was noted over the . . .
AB0711 Polymyalgia rheumatica: is it under-represented at rheumatology conferences?
Authors: S. Hider, S. Muller, E. Roddy, C. Mallen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Polymyalgia Rheumatica (PMR) has been cited as the commonest inflammatory rheumatological disorder in the over 50s with a life time prevalence of 2.4% in females &amp; 1.7% in males<sup>1</sup>. In addition it is one of the most frequent indications for long term steroid treatment. Despite this there appears to be a relative dearth of research into PMR compared to other inflammatory conditions such as gout (prevalence 1.4%<sup>2</sup>), rheumatoid arthritis (RA, prevalence 1%<sup>3</sup>) or psoriatic arthritis (PsA, prevalence 0.2%<sup>4</sup>). <h3>Objectives</h3> To compare the number of presentations (oral or poster) relating to PMR with the number relating to PsA, gout and RA at the EULAR Congress and the British Society for Rheumatology (BSR) from 2010-2012. <h3>Methods</h3> Automated electronic searches of the EULAR Abstract Archive and the online BSR abstract book were conducted for the terms ("Polymyalgia Rheumatica" OR "PMR"), "Psoriatic Arthritis", "Gout" and ("Rheumatoid arthritis" OR "RA") in the titles of all oral and poster presentations for each of the years 2010, 2011 and 2012. <h3>Results</h3> Over the three year period, at the EULAR Congress 52 presentations with PMR in the title were identified. Over the same period, there were 148 presentations relating to gout, 287 relating to PsA, and 2513 relating to RA at this meeting. This corresponds to 2.8 gout, 5.5 PsA and 48.3 RA presentations for every PMR presentation. Similarly, over this period at the BSR, there were 7 presentations on PMR compared to 19 on gout, 40 on PsA and 301 on RA. This equates to 2.7 gout presentations, 5.7 PsA presentations and 43.0 RA presentations per PMR presentation. <h3>Conclusions</h3> There is a striking under-representation of PMR at both the EULAR Congress and the BSR, relative to the prevalence of this condition. This is particularly marked when compared to psoriatic arthritis, which may reflect the perceived severity of the condition or indeed the likelihood of the disease being managed in secondary care. Overall, there is a striking mismatch between the prevalence of disease and frequency with which research findings are presented at international rheumatology conferences. <h3>References</h3> Crowson CS, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633-9. Annemans L, et al. Gout in the UK and Germany: Prevalence, co-morbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–966 Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):s295-302. Ogdie A, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2012 Dec 7. [Epub] <h3>Disclosure of Interest</h3> None Declared
Endoscopic treatment of nonstricture-related benign biliary diseases using covered self-expandable metal stents
Authors: Shayan Irani, Todd Baron, Ryan Law, Ali Akbar, Andrew Ross, Michael Gluck, Ian Gan, Richard Kozarek
Journal: Endoscopy (2014)

<b>Background and study aims: </b>Nonstricture benign biliary diseases (BBDs) such as leaks, perforations, and bleeding, have been traditionally managed by placement of one or more plastic stents. Emerging data support the use of covered, self-expandable, metal stents (CSEMSs). The aim of this study was to assess the outcomes of endoscopic temporary placement of CSEMS in patients with nonstricture BBD. <b>Patients and methods:</b> This was a retrospective study of CSEMS placement for BBD between May 2005 and August 2013 at two tertiary care centers. The main outcome measures were resolution of perforation, bleeding, leak, and adverse events related to CSEMS treatment. <b>Results: </b>A total of 87 patients were included (median age 62 years [range 18 – 86]). Indications for stent placement were bile leaks (n = 35, 40 %), bleeding (n = 27, 31 %), perforation (n = 18, 21 %), and other conditions (n = 7, 8 %). Fully and partially covered 8 – 10-mm diameter CSEMS were placed and subsequently removed in all 87 patients (100 %). Resolution of the underlying problem was achieved for 33 bile leaks (94 %), 25 bleedings (93 %), 18 perforations (100 %), and for 3 cases with other indications (43 %). The median duration of stenting was 9 weeks in patients with biliary leaks, 3 weeks for bleeding, and 9.5 weeks for perforations. Median follow-up was 82 weeks after stent removal. Seven adverse events occurred, including cholangitis in six patients (7 %), and tissue hyperplasia leading to difficulty in the removal of a partially covered SEMS in one patient. <b>Conclusions</b>: Nonstricture BBD can be effectively and safely treated with the short term placement of CSEMS.
Abstract 3010: Allele-specific loss of OSGIN1 associates with the progression of hepatocellular carcinoma.
Authors: Ming Liu, Yan Li, Leilei Chen, Tim Chan, Xin-Yuan Guan
Journal: Cancer Research (2013)

Abstract Hepatocellular carcinoma (HCC) is one of the most frequent human malignances worldwide, which causes more than half a million death every year. Most human cancers are characterized by genomic instability. Chromosomal region gains or losses occur during cancer progression and high incidence of allelic imbalance is often observed in cancer patients. The risk alleles were usually overrepresented in cancer cells due to selective retention or amplification. In this report, we found a novel nucleotide variation at the coding region of the gene OSGIN1. Allele imbalance of OSGIN1 was frequently observed in a cohort of HCC patients, and the wild type allele was preferentially lost in the tumor tissue. Functional assays revealed that OSGIN1 has strong tumor suppressive function and associated with chemoresistance of HCC cell lines. The variant allele was less effective in inducing apoptosis than the wild type allele. This functional variation may be due to their different ability to localize to mitochondria. Further more, we found HCC patients carrying the variant allele have poorer prognosis than the wild type carriers. These findings suggested that OSGIN1 might be an important tumor suppressor gene in the progression of HCC and the retention of the variant allele might be a risk factor for HCC. Citation Format: Ming Liu, Yan Li, Leilei Chen, Tim Chan, Xin-Yuan Guan. Allele-specific loss of OSGIN1 associates with the progression of hepatocellular carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3010. doi:10.1158/1538-7445.AM2013-3010
Tobacco Products Litigation
Authors: R. B. SKLAROFF
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Tobacco Products Litigation Get access ROBERT B. SKLAROFF, M.D. ROBERT B. SKLAROFF, M.D. Associates Medical Oncology/Hematology 1335 West Tabor Rd, Philadelphia, PA 19141-3038 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 11, 3 August 1988, Page 875, https://doi.org/10.1093/jnci/80.11.875 Published: 03 August 1988
The microvasculature of invasive ductal breast carcinoma: a sterological approach.
Authors: S Mahon, N Miller, C Curran, P Dockery, G Callagy, MJ Kerin
Journal: Cancer Research (2009)

Abstract Abstract #1057 Background:&amp;#x2028; Microvessel density (MVD) is a commonly used parameter to describe tumour vascularity and has been widely studied as a possible prognosticator in breast cancer. Other descriptors of vascular beds have been developed and have been applied to a variety of systems including the reproductive and nervous systems. These stereological approaches are providing objective unbiased assessment of various vascular beds.&amp;#x2028; Aim:&amp;#x2028; The aim of this pilot study was to use stereological methods to describe the vasculature in invasive ductal breast carcinoma, to test the hypothesis that microvasculature anatomy effects Tumor Grade, Size and Nodal Status.&amp;#x2028; Methods:&amp;#x2028; A cohort of 51 breast cancer patients with pre-menopausal invasive ductal carcinoma and moderate NPI was identified.Sections were stained with CD34 using the automated Ventana Discovery staining platform. A number of stereological parameters were estimated in three tissue compartments (gland,stroma and adipose):Number per Unit area (Na), Length Density (Lv) and Radial Diffusion Distance. Data was analysed using Analyses of Variance methods using Minitab© Statistical software.&amp;#x2028; Results:&amp;#x2028; There was no significant difference in the radial diffusion difference when groups were analysed by Grade Size and Nodal Status. Similar results were found for Na and Lv&amp;#x2028; Conclusion:&amp;#x2028; This study suggests that there is no simple link between tumor vasculature and Grade, size and nodal status in Invasive Ductal Breast Carcinoma. This study illustrates the potential usefulness of the stereological approach in the study of vascular beds in breast cancer studies by providing access to potentially physiologically relevant anatomical parameters of microvasculature beds. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1057.
102nd Congress' Attention to Cancer Remains Significant
Authors: S. Bennett
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article 102nd Congress' Attention to Cancer Remains Significant Get access Sylvia Bennett Sylvia Bennett Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 11, 3 June 1992, Pages 841–842, https://doi.org/10.1093/jnci/84.11.841 Published: 03 June 1992
Fertility Treatments and Multiple Births in the United States
Authors: Aniket D. Kulkarni, Denise J. Jamieson, Howard W. Jones, Dmitry M. Kissin, Maria F. Gallo, Maurizio Macaluso, Eli Y. Adashi
Journal: New England Journal of Medicine (2013)

The advent of fertility treatments has led to an increase in the rate of multiple births in the United States. However, the trends in and magnitude of the contribution of fertility treatments to the increase are uncertain.
Matricellular Protein CCN5 Reverses Established Cardiac Fibrosis
Authors: Dongtak Jeong, Min-Ah Lee, Yan Li, Dong Kwon Yang, Changwon Kho, Jae Gyun Oh, Gyeongdeok Hong, Ahyoung Lee, Min Ho Song, Thomas J. LaRocca, Jiqiu Chen, Lifan Liang, Shinichi Mitsuyama, Valentina D'Escamard, Jason C. Kovacic, Tae Hwan Kwak, Roger J. Hajjar, Woo Jin Park
Journal: Journal of the American College of Cardiology (2016)
Postprandial Glucose and Insulin Responses to Meals Containing Different Carbohydrates in Normal and Diabetic Subjects
Authors: John P. Bantle, Dawn C. Laine, Gay W. Castle, J. William Thomas, Byron J. Hoogwerf, Frederick C. Goetz
Journal: New England Journal of Medicine (1983)

To examine whether the form of dietary carbohydrate influences glucose and insulin responses, we studied the glucose and insulin responses to five meals--each containing a different form of carbohydrate but all with nearly identical amounts of total carbohydrate, protein, and fat--in 10 healthy subjects, 12 patients with Type I diabetes, and 10 patients with Type II diabetes. The test carbohydrates were glucose, fructose, sucrose, potato starch, and wheat starch. In all three groups, the meal containing sucrose as the test carbohydrate did not produce significantly greater peak increments in the plasma concentration of glucose or greater increments in the area under the plasma glucose-response curves than did meals containing potato, wheat, or glucose as test carbohydrates. Urinary excretion of glucose in patients with diabetes was not significantly greater after the sucrose meal. The meal containing fructose as the test carbohydrate produced the smallest increments in plasma glucose levels, but the differences were not always statistically significant. In healthy subjects and patients with Type II diabetes, peak serum concentrations of insulin were not significantly different in response to the five test carbohydrates. Our data do not support the view that dietary sucrose, when consumed as part of a meal, aggravates postprandial hyperglycemia.
Taking the Guesswork Out of Uveal Melanoma
Authors: Meenhard Herlyn, Katherine L. Nathanson
Journal: New England Journal of Medicine (2010)

Therapy for melanoma is making remarkable progress. Only 8 years after the initial discovery of mutations in the BRAF oncogene, a new small-molecule inhibitor specific for mutant BRAF, PLX4032 (also known as RG7204), induced tumor shrinkage in more than 80% of patients with cutaneous melanoma containing BRAF mutations and extended progression-free survival by an average of 7 months.1,2 Although BRAF-targeted therapy is not curative, it is possible that its combination with immunotherapy to potentiate antitumor T-cell responses may lead to durable responses.3 The mutant BRAF amino acid that is targeted by PLX4032 is present in 50% of cutaneous melanomas . . .
Shark Endangerment Concerns Researchers
Authors: J. Mathews
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Shark Endangerment Concerns Researchers Get access James Mathews James Mathews Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 13, 1 July 1992, Page 1001, https://doi.org/10.1093/jnci/84.13.1001 Published: 01 July 1992
Abstract 4111: EGFR gene mutation as a predictive marker of the response to pemetrexed-based chemotherapy in non-small cell lung cancer
Authors: Koyama Nobuyuki, Rinako Sadakata, Hitoshi Miyazawa, Koichi Hagiwara, Kunihiko Kobayashi
Journal: Cancer Research (2011)

Abstract [Background] Pemetrexed (PEM) is an antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, and one of standard anti-cancer agents against non-small cell lung cancer (NSCLC), particularly non-squamous cell carcinoma, whereas there is insufficient evidence for clinical practice. [Methods] We retrospectively studied 111 NSCLC cases treated with PEM-based chemotherapy in our institute to analyze the correlation of clinicopathological characteristics with the therapeutic effect of PEM. Furthermore, the validation of identified factors from the analysis was also conducted, using in vitro assays. [Results] The therapeutic effect of PEM plus carboplatin was comparable to that of PEM plus cisplatin from χ2 test. Kaplan-Meier survival analysis and logrank test showed that in the patients receiving PEM-based chemotherapy, epidermal growth factor receptor (EGFR) gene mutation was significantly correlated with the therapeutic effect and progression free survival but not overall survival. From IC50 of PEM, NSCLC cells with mutant EGFR were significantly sensitive to those with wild-type EGFR. [Conclusion] EGFR gene mutation can be a predictive marker of the response to PEM-based chemotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4111. doi:10.1158/1538-7445.AM2011-4111